Article Information
History
- January 10, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 10, 2022 - 02:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Lyn R. Frumkin1,¶,
- Michaela Lucas2,¶,
- Curtis L. Scribner3,
- Nastassja Ortega-Heinly4,
- Jayden Rogers5,
- Gang Yin6,
- Trevor J Hallam6,
- Alice Yam6,
- Kristin Bedard6,
- Rebecca Begley1,
- Courtney A. Cohen7,8,
- Catherine V. Badger7,
- Shawn A. Abbasi7,
- John M. Dye7,
- Brian McMillan9,
- Michael Wallach10,
- Traci L. Bricker11,
- Astha Joshi11,
- Adrianus C.M. Boon11,
- Suman Pokhrel12,
- Benjamin R. Kraemer12,
- Lucia Lee12,
- Stephen Kargotich13,
- Mahima Agogiya1,
- Tom St. John14 and
- Daria Mochly-Rosen1,12,13,*
- 1SPARK at Stanford, Stanford University, School of Medicine, Stanford, California, United States of America
- 2Faculty of Health and Medical Sciences Internal Medicine, The University of Western Australia, Perth, Western Australia, Australia
- 3Independent Regulatory Consultant, Oakland, California, United States of America
- 4Avian Vaccine Services, Charles River Laboratories, Storrs, Connecticut, United States of America
- 5Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
- 6Sutro Biopharma Inc., South San Francisco, California, United States of America
- 7United States Army Medical Research Institute of Infectious Diseases, Virology Division, Frederick, Maryland, United States of America
- 8The Geneva Foundation, Tacoma, Washington, United States of America
- 9Bravado Pharmaceuticals, Lutz, Florida, United States of America
- 10University of Technology Sydney, Sydney, New South Wales, Australia and SPARK Sydney, Sydney, New South Wales, Australia
- 11Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America
- 12Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, California, United States of America
- 13SPARK Global, Stanford University, School of Medicine, Stanford, California, United States of America
- 14Independent Scientist, Woodway, Washington, United States of America
- ↵*Corresponding author. Email: mochly{at}stanford.edu (D.M-R)
↵¶ These authors contributed equally to this work.
Posted January 10, 2022.
Egg-derived anti-SARS-CoV-2 immunoglobulin Y (IgY) with broad variant activity as intranasal prophylaxis against COVID-19: preclinical studies and randomized controlled phase 1 clinical trial
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
3
Blogs/Media
Author Videos